Overview

ALS Phase II Study of NX210c

Status:
RECRUITING

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

This study will investigate the efficacy, safety, tolerability and pharmacokinetics (PK) of multiple intravenous infusions of NX210c, at two dose levels, in patients with Amyotrophic lateral sclerosis (ALS).

Phase:

PHASE2

Details

Lead Sponsor:

Axoltis Pharma

Collaborator:

ACT4ALS network